ArticleJACC. Asia2026
Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04153149 (HELIOS-B), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Who cites it
1 citing paper in PubMed.
- Cardiac Amyloidosis in Asia: What We Know and Don't Know.JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the phase III Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (HELIOS-B), vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events and preserved functional capacity and quality of life. However, data in East Asian populations remain limited.
objectivesThe authors aimed to assess the efficacy and safety of vutrisiran in East Asian patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) enrolled in HELIOS-B.
methodsThis post-hoc analysis included 32 patients from Japan and South Korea randomized to vutrisiran (n = 17) or placebo (n = 15). The primary endpoint was a composite of all-cause mortality and recurrent cardiovascular events for up to 36 months. Secondary endpoints were changes from baseline to month 30 in the 6-minute walk test distance, Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score, and New York Heart Association (NYHA) functional class. Exploratory endpoints included changes in N-terminal pro-B-type natriuretic peptide and troponin I. Safety was also evaluated.
resultsBaseline characteristics were generally similar to the overall population, although baseline tafamidis use was lower in East Asian patients. Vutrisiran reduced the risk of the composite primary endpoint vs placebo (HR: 0.20; 95% CI: 0.04-0.93). Vutrisiran attenuated declines in 6-minute walk test distance and KCCQ-OS scores, and a greater proportion of patients maintained or improved NYHA functional class. Smaller increases in N-terminal pro-B-type natriuretic peptide and troponin I levels were observed with vutrisiran vs placebo. Similar trends were observed in patients not receiving baseline tafamidis. Safety was consistent with the overall population.
conclusionsIn East Asian patients with ATTR-CM from HELIOS-B, the efficacy and safety of vutrisiran were consistent with the overall population. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.